**Supplementary Table 2. Univariate and multivariate1 analysis for determinants of secondary loss of response in infliximab treated patients.**

|  |  |
| --- | --- |
|   | **Infliximab (n=44)** |
| **Unadjusted** | **p-value** | **Age- and gender-adjusted** | **p-value** | **Multivariate regression** | **p-value** |
| **Abdominal Circumference** | 1.02 (0.99, 1.06) | 0.21 | 1.03 (0.99, 1.07) | 0.17 | 0.995 (0.952, 1.041) | 0.84 |
| **Visceral Fat Area** | **1.005 (1.000, 1.009)** | **0.03** | **1.007 (1.002, 1.013)** | **0.01** | 1.001 (0.996, 1.007) | 0.64 |
| **Subcutaneous Fat Area** | 1.001 (0.997, 1.006) | 0.53 | 1.001 (0.997, 1.006) | 0.63 | 1.000 (0.993, 1.006) | 0.89 |
| **Total fat area** | 1.003 (1.000, 1.006) | 0.08 | 1.003 (1.000, 1.006) | 0.09 | 1.001 (0.996, 1.005) | 0.79 |
| **Skeletal Muscle Area** | 1.003 (0.993, 1.012) | 0.60 | 1.016 (0.999, 1.033) | 0.06 | 1.002 (0.992, 1.012) | 0.70 |
| **Visceral Fat Area corrected for Stature** | **1.015 (1.001, 1.028)** | **0.03** | **1.020 (1.004, 1.037)** | **0.02** | 1.004 (0.986, 1.021) | 0.69 |
| **VFI (<30)** | **Reference** | **-** | **Reference** | **-** | **Reference** | **-** |
| **VFI (30-60)** | **2.36 (0.80, 7.00)** | **0.12** | **3.17 (0.93, 120.81)** | **0.07** | 2.14 (0.55, 8.39) | 0.28 |
| **VFI (>60)** | **3.59 (1.08, 11.90)** | **0.04** | **5.36 (1.30, 22.16)** | **0.02** | 1.58 (0.39, 6.51) | 0.53 |
| **Skeletal Muscle Area corrected for Stature** | 1.01 (0.98, 1.04) | 0.49 | 1.04 (0.99, 1.08) | 0.09 | 1.01 (0.97, 1.05) | 0.68 |
| **VFA/SMA** | **2.67 (1.13, 6.29)** | **0.03** | **3.24 (1.17, 8.96)** | **0.02** | 1.40 (0.48, 4.08) | 0.54 |
| **Body Mass Index kg/m2** | 1.08 (0.99, 1.17) | 0.08 | **1.091 (1.003, 1.187)** | **0.04** | 1.06 (0.97, 1.17) | 0.19 |
| 1Multivariate regression adjustment for Montreal age groups (A1≤16, A2=17-40, A3>40), trough level, smoking status (active/ inactive) at the time of CT/ MRI, antibody seropositivity (>100 IU/ml), concurrent immunomodulator use (thiopurines or methotrexate) |